Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is poised for substantial growth, with projected risk-adjusted revenues from its Cushing’s syndrome indication expected to rise significantly, reaching nearly $824 million by 2030, up from $175 million in 2026, supported by a high probability of a successful product launch. The company has also reported record increases in Korlym prescribers and patients, which can be attributed to enhanced physician awareness and effectively addressing hypercortisolism. Additionally, the potential success of the selective cortisol modulator, relacorilant, could introduce an additional $400 million to $500 million in annual revenue, particularly if adopted in challenging patient demographics such as resistant hypertension and difficult-to-control diabetes.

Corcept Therapeutics faces significant operational challenges that could lead to decreased revenue in 2025 as the company works to meet demand for its drug, Korlym. There is a concerning lack of awareness and data among prescribing doctors, with 70% of surveyed physicians citing limited understanding of the drug as a barrier to adoption, and misconceptions about the prevalence of hypercortisolism further complicating efforts for successful treatment. Additionally, factors such as drug cost and safety concerns contribute to hesitancy in prescribing Korlym, highlighting substantial barriers that could impede the company's growth and market penetration.